Hypertension in Chronic Kidney Disease

被引:143
作者
Hamrahian, Seyed Mehrdad [1 ]
Falkner, Bonita [1 ]
机构
[1] Thomas Jefferson Univ, Sidney Kimmel Sch Med, Dept Med, Div Nephrol, 833 Chestnut St,Suite 700, Philadelphia, PA 19107 USA
来源
HYPERTENSION: FROM BASIC RESEARCH TO CLINICAL PRACTICE, VOL 2 | 2017年 / 956卷
关键词
Hypertension; Blood pressure; Adults; Chronic kidney disease; Ambulatory blood pressure monitoring; White coat hypertension; Masked hypertension; Sodium; Salt; Resistant hypertension; BLOOD-PRESSURE-MEASUREMENT; AMERICAN-HEART-ASSOCIATION; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TREATMENT-RESISTANT HYPERTENSION; CLINICAL-PRACTICE GUIDELINES; TYPE-2; DIABETES-MELLITUS; TARGET ORGAN DAMAGE; CARDIOVASCULAR RISK; INTERNATIONAL-SOCIETY; RENAL DENERVATION;
D O I
10.1007/5584_2016_84
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Hypertension, a global public health problem, is currently the leading factor in the global burden of disease. It is the major modifiable risk factor for heart disease, stroke and kidney failure. Chronic kidney disease (CKD) is both a common cause of hypertension and CKD is also a complication of uncontrolled hypertension. The interaction between hypertension and CKD is complex and increases the risk of adverse cardiovascular and cerebrovascular outcomes. This is particularly significant in the setting of resistant hypertension commonly seen in patient with CKD. The pathophysiology of CKD associated hypertension is multi-factorial with different mechanisms contributing to hypertension. These pathogenic mechanisms include sodium dysregulation, increased sympathetic nervous system and alterations in renin angiotensin aldosterone system activity. Standardized blood pressure (BP) measurement is essential in establishing the diagnosis and management of hypertension in CKD. Use of ambulatory blood pressure monitoring provides an additional assessment of diurnal variation in BP commonly seen in CKD patients. The optimal BP target in the treatment of hypertension in general and CKD population remains a matter of debate and controversial despite recent guidelines and clinical trial data. Medical therapy of patients with CKD associated hypertension can be difficult and challenging. Additional evaluation by a hypertension specialist may be required in the setting of treatment resistant hypertension by excluding pseudo-resistance and treatable secondary causes. Treatment with a combination of antihypertensive drugs, including appropriate diuretic choice, based on estimated glomerular filtration rate, is a key component of hypertension management in CKD patients. In addition to drug treatment non- pharmacological approaches including life style modification, most important of which is dietary salt restriction, should be included in the management of hypertension in CKD patients.
引用
收藏
页码:307 / 325
页数:19
相关论文
共 120 条
[21]   Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus Results From the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial [J].
Chalmers, John ;
Arima, Hisatomi ;
Woodward, Mark ;
Mancia, Giuseppe ;
Poulter, Neil ;
Hirakawa, Yoichiro ;
Zoungas, Sophia ;
Patel, Anushka ;
Williams, Bryan ;
Harrap, Stephen .
HYPERTENSION, 2014, 63 (02) :259-+
[22]  
Ciobanu Andrea O, 2013, Maedica (Bucur), V8, P129
[23]   Parallel-Group 8-Week Study on Chlorthalidone Effects in Hypertensives With Low Kidney Function [J].
Cirillo, Massimo ;
Marcarelli, Fabiana ;
Mele, Alessandra A. ;
Romano, Massimo ;
Lombardi, Cinzia ;
Bilancio, Giancarlo .
HYPERTENSION, 2014, 63 (04) :692-697
[24]   Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis [J].
Clark, Christopher E. ;
Taylor, Rod S. ;
Shore, Angela C. ;
Ukoumunne, Obioha C. ;
Campbell, John L. .
LANCET, 2012, 379 (9819) :905-914
[25]   Home Blood Pressure Monitoring in CKD [J].
Cohen, Debbie L. ;
Huan, Yonghong ;
Townsend, Raymond R. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 63 (05) :835-842
[26]   Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients [J].
Conlin, PR ;
Moore, TJ ;
Swartz, SL ;
Barr, E ;
Gazdick, L ;
Fletcher, C ;
DeLucca, P ;
Demopoulos, L .
HYPERTENSION, 2000, 36 (03) :461-465
[27]   The Cooperative Roles of Inflammation and Oxidative Stress in the Pathogenesis of Hypertension [J].
Crowley, Steven D. .
ANTIOXIDANTS & REDOX SIGNALING, 2014, 20 (01) :102-120
[28]   Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus [J].
Cushman, William C. ;
Evans, Gregory W. ;
Byington, Robert P. ;
Goff, David C., Jr. ;
Grimm, Richard H., Jr. ;
Cutler, Jeffrey A. ;
Simons-Morton, Denise G. ;
Basile, Jan N. ;
Corson, Marshall A. ;
Probstfield, Jeffrey L. ;
Katz, Lois ;
Peterson, Kevin A. ;
Friedewald, William T. ;
Buse, John B. ;
Bigger, J. Thomas ;
Gerstein, Hertzel C. ;
Ismail-Beigi, Faramarz .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (17) :1575-1585
[29]   High prevalence of cardiac and extracardiac target organ damage in refractory hypertension [J].
Cuspidi, C ;
Macca, G ;
Sampieri, L ;
Michev, I ;
Salerno, M ;
Fusi, V ;
Severgnini, B ;
Meani, S ;
Magrini, F ;
Zanchetti, A .
JOURNAL OF HYPERTENSION, 2001, 19 (11) :2063-2070
[30]   Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].
Dahlöf, B ;
Sever, PS ;
Poulter, NR ;
Wedel, H ;
Beevers, DG ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2005, 366 (9489) :895-906